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abirateroneprednisone (AbP) improve overall survival (OS) in patients with
mCRPC vs. mitoxantroneP (MP) or P alone, respectively. Examination of patient
and disease characteristics noted differences in the exposure to docetaxel and
discontinuation of docetaxel due to progressive disease. The current study: 1) con-
ducted systematic literature reviews of second-line treatment studies; 2) reviewed
NICE and IQWIG submissions; 3) reviewed the initial and updated OS data from the
TROPIC and COU-AA-301 studies; 4) interviewed clinical experts; and 5) performed
a meta-analysis of two first-line (1L) mCRPC studies to inform the ITC on the OS for
the two treatments and connect the network. Three comparisons were performed
using hazard ratios (HRs) for the MP vs. P: 1.0 (clinical expert opinion), 0.97 (1L
studies meta-analysis), and 0.90 (survival curve extraction). The Bucher ITC was
used with a HR (CbzP vs. AbP)1 favoring CbzP.RESULTS:Results based on updated
OS data were consistent across methodologies, with HR(OS, clinical)0.97 (95%CI:
0.78-1.21), HR(OS, meta-analysis)0.95 (95%CI: 0.69-1.30) and HR(OS, extrac-
tion)0.88 (95%CI: 0.63-1.21), but all HRs were not significantly different. This was
observed in the docetaxel-resistant subgroup as well; with HR(OS, clinical) 0.95
(95%CI: 0.70-1.28), HR(OS, meta-analysis) 0.92 (95%CI: 0.63-1.34) and HR(OS, ex-
traction)0.85 (95%CI: 0.59-1.24). These are different from the results presented in
the IQWIG submission assuming that MP has the same effect as P alone based on
initial OS data. CONCLUSIONS: Differences in results highlight the dependency of
ITCs on efficacy assumptions. Lack of equivalence in disease, comparators or pa-
tient characteristics contribute to uncertainty regarding conclusions, which fur-
ther emphasizes the fact that randomized prospective clinical trials are best suited
to fully evaluate the efficacy and safety of cancer treatments.
RESEARCH ON METHODS - Patient-Reported Outcomes Studies
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CROSS-CULTURAL VALIDATION OF THE HUNTINGTON QUALITY OF LIFE
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OBJECTIVES: The Huntington Quality of Life Instrument (H-QoL-I) is the first self-
reported, disease-specific instrument developed to assess the health-related qual-
ity of life (HRQoL) of patients with Huntington’s disease (HD). It was originally
developed and validated for France and Italy, and later also validated for Germany,
Poland and the USA. This study aimed to validate the Spanish version of H-QoL-I
cross-culturally. METHODS: The original questionnaire included three subscales
assessing motor functioning, psychology and socializing (11 items). The instru-
ment was translated forwards and backwards by native speakers. A survey was
conducted with 59 patients. Face validity was tested through item completion and
overall understanding. Internal validity was tested, assessing internal consistency,
correlation matrix using item/dimension correlation and factorial structure. Exter-
nal validation was performed versus motor symptoms, behavioral symptoms, in-
dependence, and the EuroQoL 5D (EQ-5D). Differential item functioning (DIF) anal-
yses were performed versus data from the Italian and French versions, using
Zumbo criteria. RESULTS: Item response rates ranged from 87% to 97%. A floor
effect was found for three items. Results showed that the scale had a good reliabil-
ity (Cronbach’s alpha coefficients  0.75). Factor analyses demonstrated satisfac-
tory construct validity. Item internal consistency (IIC) and item discriminant valid-
ity criteria were met for most items (i.e. IIC was  0.40, and correlations between
items and their respective rest-scores in one dimension were all greater than cor-
relations with another dimension). The external validity was supported by corre-
lation of the different dimensions with the related clinical symptoms and related
generic QoL dimensions. The correlation between total H-QoL-I score and EQ-5D
index score was 0.78. No DIF was detected. CONCLUSIONS: These data support the
cross-cultural validity of the H-QoL-I to assess the health status of patients with HD
and integrate the patient perspective for Spain. A limitation of this study is the
small sample size.
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OBJECTIVES: To translate and examine the psychometric properties of the Malay-
sian version of the Osteoporosis Health Belief Scale (OHBS-M) among type 2 diabe-
tes patients (T2DM) and to determine the best cut-off value for OHBS-M with opti-
mum sensitivity and specificity. METHODS: A standard “forward–backward”
procedure was used to translate OHBS into Malay language. It was later validated
on a convenience sample of 250 T2DM outpatients between May and July 2011. The
psychometric assessment of this study was including validity (face validity, con-
tent validity ratio, and construct validity) and reliability (internal consistency and
test-retest). Sensitivity and specificity of OHBS-M were calculated using receiver
operating characteristic (ROC) curve analysis in comparison with the proxy gold
standard (quantitative ultrasound scan). RESULTS: The mean SD of OHBS-M
scores was 158.31 20.80. The Fleiss’ kappa, content validity ratio range and con-
tent validity index were 0.99, 0.75 to 1 and 0.886, respectively. Seven factors of the
OHBS-M were identified using exploratory factor analysis and were confirmed
through confirmatory factor analysis. Internal consistency and test–retest reliabil-
ity value were 0.89 and 0.61, respectively. The cut-off value of the OHBS-M was 169
with a sensitivity of 77.4% (95% CI 0.68- 0.84) and a specificity of 78.2% (95% CI 0.69-
0.85) to identify osteoporosis/osteopenia patients. The positive and negative pre-
dictive values were 78% (95% CI 0.68 - 0.85) and 77.6% (95% CI 0.68-0.84), respec-
tively. The area under the curve (AUC) for the OHBS-M was 0.877(95% CI 0.82-0.92).
According to QUS measurements, 20.4% were considered osteoporotic, while, 57.6
% osteopenic and 22 % normal. CONCLUSIONS: The findings of this study suggest
that the OHBS-M instrument is valid and reliable tool to be used in Malaysian
clinical setting.
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OBJECTIVES: Item response theory (IRT) modeling evaluated the metric underlying
generic physical function (PF) surveys including SF-36, PROMIS and new PF cate-
gorical rating items and tested whether scores could be estimated more efficiently
while maintaining forward-backward comparability. METHODS: Generalized Par-
tial Credit Model (GPCM) estimates of parameters for MOS SF-36 PF-10, PROMIS
6-item PF and new (easy-hard) PF categorical rating items and model fit were tested
in a probability sample representing the general US population (N 625). Analyses
included: (a) fit of GPCM for 35-item bank; (b) item utilization in computerized
adaptive tests (CAT), (c) % at ceiling and floor; (d) % for whom reliability  0.90
(reliable range); (e) equivalence of mean norm–based scores (mean50, SD10) for
all measures across mild, moderate and severe chronically-ill groups, and (f) valid-
ity in predicting physical and emotional health general summary measures at a
9-month follow-up. RESULTS: The GPCM fit the data and item parameter estimates
agreed very well with those previously reported for MOS and PROMIS PF items. In
tests of discriminant validity, group means differed substantially across severity
groups (RV 0.81 to 1.00) and score equivalence across methods within each group
was confirmed (all differences 1 point). RV’s for standardized PF scores estimated
from new E-H items were equivalent to PF-10 and PROMIS PF estimations. Predic-
tive validity was equivalent and substantial (across methods) for physical and
significant, but lower, for emotional outcomes at 9 months, as hypothesized. The
most efficient (reduced respondent burden, comparable or improved reliability and
validity) measure was a new 6-item PF using E-H items and an improved adaptive
survey logic. CONCLUSIONS: Findings support the standardization of the metric
underlying PF measures and extend choice of methods to include more efficient
categorical rating scales that maintain forward-backward score comparability. Im-
proved adaptive survey logic reduces respondent burden and increases the reliable
range for estimates of scores for familiar legacy measures. This approach warrants
application to other generic health domains and tests of translated items and
standardized parameters across countries and languages.
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OBJECTIVES: A utility value is a preference-based measure for a person’s health-
related quality of life at a given point in time. In clinical trials the standard is to
measure utilities based on e.g. EQ-5D or HUI-3. However, in rheumatoid arthritis
(RA) there has been a tradition of estimating utility values indirectly from HAQ-DI.
This study used data from a phase 2a trial in RA patients after treatment with
NNC0109-0012 to assess outcome differences applying various indirect mapping
algorithms. METHODS: At least five different indirect mapping algorithms (UV1-5)
that translates HAQ-DI to EQ-5D or HUI3 utility values have been published. These
were applied to a phase 2a, multicentre, randomised, double-blind, multiple-dose,
placebo-controlled, parallel group trial investigating the clinical efficacy of
NNC0109-0012 in RA patients with active disease (Results reported elsewhere).
Physical function was a secondary objective measured by the change in HAQ-DI
from baseline to week 12. The analysis was performed with an ANOVA with treat-
ment as fixed factor. The following five algorithms were used: UV1(EQ-5D)0.9567–
0.309*HAQ-DI, Min;Max(0.03;0.96); UV2(HUI3)0.76–0.28*HAQ-DI0.05*(if Fe-
male), Min;Max(-0.08;0.81); UV3(HUI3)0.76–0.28*HAQ-DI0.05*(if
Female)0.001*Age, Min;Max(-0.06;0.91); UV4(HUI3)0.74–0.17*HAQ-DI, Min;
Max(0.23;0.74); and UV5(HUI3)0.9527–0.2018*HAQ-DI, Min;Max(0.35;0.95).
RESULTS: After 12 weeks the mean utility improvement within the active-group
across algorithms was 0.11 (range: 0.08-0.14) and 0.03 (range: 0.02-0.05) in the pla-
cebo-group. When comparing utility improvements between active and placebo
group across algorithms the difference was most pronounced when using UV3 
0.10 (range: 0.06-0.10) taking HAQ-DI, sex and age into account. CONCLUSIONS:
Choice of mapping algorithm for conversion of HAQ-DI into utilities impacts the
outcome in term of utility improvements, although the differences are small. Fu-
ture clinical trials using direct assessment of utilities will substantiate the potential
benefits of NNC0109-0012 for patients suffering from RA. Direct elicitations can
also be used to shed additional light on the validity of available indirect mapping
algorithms.
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HOW DO PATIENTS WITH DIFFERENT CONDITIONS DESCRIBE THEIR PAIN?
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OBJECTIVES: To identify descriptors that patients who have different physical con-
ditions use to describe the quality and severity of their pain, and to examine com-
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mon use across and between conditions. METHODS: Subjects were recruited by
web posting and telephone screening. Those self-reporting active treatment for
one of four conditions (Migraine, Low Back Pain (LBP), Osteo-Arthritis (OA), Rheu-
matoid Arthritis (RA)) were scheduled for in-person interviews using card sort
exercises with 54 different pain descriptors to identify those each subject com-
monly used to describe the pain associated with their condition. RESULTS: Sub-
jects ranged between 29 and 63 years (mean age of 45). The majority (71%) was
female, 60% were working full or part time, and 51% were Caucasian. Pain descrip-
tors were divided into three groups based on percent of subject endorsement;
70-100% for high use 45-69% for moderate use, and 18-44% for low use. Across all
four conditions, the most used pain descriptors were SHARP, ACHING, THROB-
BING, and HURTING. Moderate use was shown across all conditions for terms like
RADIATING, SPREADING, STINGING, and JOLTING. Lower percentages of study sub-
jects used descriptors with more specific pain characteristics, including tempera-
ture (HOT, SEARING, BURNING), neuropathic characteristics (NUMB, PRICKLING)
and qualities associated with acute pain (CUTTING, TEARING). Migraine subjects
tended to use descriptors like POUNDING (83%), SPLITTING (88%) and PULSATING
(77%). LBP subjects used STABBING (77%), PINCHING (84%), and SHOOTING (74%).
OA and RA patients tended to be more similar with CONSTANT (46%/73%), TENDER
(55%/64%) and SORE (72/73%). Additional descriptors unique to RA included TIGHT
(73%) and CRAMPING (64%). CONCLUSIONS: Because descriptors of pain used by
patients across these four different conditions showed use of similar language as
well as expressions that were unique to their condition, the assessment of condi-
tion specific pain should be considered when planning to use pain as a study
endpoint.
PRM92
EXPLORATORY MAPPING OF THE LUPUSQOL TO THE SF-6D
Meacock R1, Harrison M1, Mcelhone K2, Isenberg D3, Ferenkeh-Koroma A4, Ahmad Y5,
Bruce IN1, Shelmerdine J6, Gordon C7, Griffiths B8, Maddison P9, Akil M10, Abbott J11, Teh
LS2
1University of Manchester, Manchester, UK, 2Royal Blackburn Hospital, Blackburn, UK,
3University College London Hospitals, London, UK, 4University College London, London, UK, 5Betsi
Cadwaldr University Health Board, Llandudno, UK, 6Macclesfield District General Hospital,
Macclesfield, UK, 7University of Birmingham, Birmingham, UK, 8Freeman Hospital, Newcastle,
UK, 9Bangor University, Bangor, UK, 10Royal Hallamshire Hospital, Sheffield, UK, 11University of
Central Lancashire, Preston, UK
OBJECTIVES: To derive a mapping algorithm to estimate scores (utility values) for
the preference-based SF-6D measures from the non-preference-based disease-
specific LupusQoL. METHODS: A total of 282 systemic lupus erythematosus (SLE)
patients completed the LupusQoL and SF-6D at the same assessment. Models of the
relationship between them were estimated using OLS regression. The SF-6D utility
score was modelled using total scores on the 8 LupusQoL domains, employing a
backward inclusion procedure. Model performance was judged using the root
mean squared error (RMSE) and range of predicted values.RESULTS:The mean (SD)
age of the sample was 45 (13.4) years and the mean (SD) SF-6D score was 0.61 (0.13).
The mean scores for the LupusQoL domains ranged from 52.5 (Fatigue) to 73.5 (Body
Image). Four of the eight LupusQoL domains were selected for inclusion in the final
model (Physical Health, Pain, Emotional Health, Fatigue) because these domains
were measured in both instruments. The root mean square error (RMSE) for the
mapping function was 0.0701, lower than that reported for many published map-
ping functions. The overall model fit was good (R20.7155), although some under
prediction at the upper end of the SF-6D was observed. CONCLUSIONS: There
appears to be a strong relationship between the LupusQoL and SF-6D. Prediction
errors are lower than for many published mapping functions, signifying that the
mapping algorithm developed here provides a methodology for predicting SF-6D
utility values from LupusQoL data. Potentially this could reduce patient burden if
all of the necessary information can be obtain from administering the LupusQoL
alone. However, the omission of disease-specific LupusQoL domains (intimate re-
lationships, body image, burden to others, planning) from the final model, raises
concerns that the specificity for SLE may be lost in this algorithm. Further out of
sample testing will be useful to confirm the performance of this algorithm.
PRM93
INFANTILE HEMANGIOMA ON FAMILIES,CREATION OF A SPECIFIC BURDEN
QUESTIONNAIRE
Boccara O1, Meni C1, Labreze C2, Bodemer C3, Voisard JJ4, Taieb C5
1Necker Hospital, Paris, France, 2Hospital Pellegrin, Bordeaux, France, 3René Descartes
University, Paris, France, 4PFD, Lavaur, France, 5CREES PFSA, Boulogne, France
OBJECTIVES: Infantile hemangioma (IH) is the most common form of benign vas-
cular tumor in children, with an estimated incidence of between 3 and 10% of
Caucasian children. The aim of our study is to develop a specific questionnaire for
assessing the burden on families of children with HI. METHODS: A “Hemangioma
Family Burden” questionnaire (HFB) consisting of 22 items. It was distributed ac-
companied by SF12 and PGWBI, to obtain internal and external validation.
RESULTS: Fifty-eight evaluable questionnaires were returned, completed by either
the mother (63.27%) or the father (36.7%). At the time of the survey, the average age
of the child with IH was 9.344.75months. Internal validity was measured by Cron-
bach’s-alpha (0.95), reflecting a good homogeneity of the 22 items.While the score
of the physical component does not vary with the expressed extent of the heman-
gioma (p0.2931), the burden scores of the SF12 mental component and the PGWBI
“wellness” component increase with “severity”, as perceived by the parents and
expressed in terms of extent. Hence, the HFB score is correlated with these 2 com-
ponents, thus confirming external validity.The mean score calculated from the HFB
is 23.4219.93. The score increases with the “severity score” of the parents. In fact,
a statistically significant difference is observed between the 3 severity groups:
5.286.8 for those reporting the smallest extent to 41.018.71 for those reporting
the greatest extent, and 27.716.96 for a moderate extent. This confirms the sen-
sitivity of the HFB. CONCLUSIONS: Internal and external validity were confirmed.
The HFB is correlated with the extent felt by parents, a feeling deemed relevant
because it is often the cause of consultation and demand for treatment. We now
have an easy-to-use, validated IH tool for assessing the disability caused. Following
cultural and linguistic validation, the HFB is now available in US English, Spanish,
German and Italian.
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OBJECTIVES: To carry out the cultural adaptation and calibration in Spain of the
universal Spanish version of two item banks previously developed and translated
by the PROMIS Group: “Pain-Behavior-PB” (39 items) and “Pain-Interference-PI” (41
items). This will allow construction of two Computerized Adaptive Tests (CATs) for
evaluating Health-Related Quality of Life (HRQoL) in patients with pain.METHODS:
Forward and backward translations of PB and PI items were carried out. The alter-
native translation was then compared to the existing PROMIS translation and re-
viewed by 25 patients and 6 experts to evaluate the relevance and comprehensi-
bility of items. Recommendations to revise the universal Spanish were evaluated
by the PROMIS Statistical Center and by a linguist from Spain. The revised items
were cognitively debriefed with 5 patients following the PROMIS Interview Script and
discrepancies were resolved. The revised universal Spanish version of both item
banks was administered to a sample of 236 subjects with chronic pain of any
etiology. Unidimensionality and local independence were evaluated. The calibra-
tion of the items was done using the Samejima’s graded response model. RESULTS:
The process of cultural adaptation of both item banks for use in Spain resulted in
the amendment of 8 items (5 PB -3 PI). Unidimensionality and local independence
of items of both banks were confirmed. Discrimination parameters ranged from
moderate to very high in almost all items of both banks. Differences according to
gender were not statistically significant in PB bank (F(1,225)3.24;p0.073) nor in PI
bank (F(1,224)2.072;p0.151). Despite the relatively small sample size, the standard
errors for the item parameters are within an acceptable range (1),with the excep-
tion of three extreme threshold parameters. CONCLUSIONS: The universal Span-
ish PROMIS Pain Behavior and Pain Interference have been calibrated in Spain and
two CATs have been built to evaluate HRQoL of patients with pain in daily clinical
practice.
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OBJECTIVES: The COPD Assessment Test (CAT) assesses the impact of chronic
obstructive pulmonary disease (COPD) on health status in clinical practice. We
examined whether the mode of administration (self vs. interviewer) influences the
CAT score and/or its psychometric properties in a heterogeneous COPD population
(during clinical stability and during exacerbations). METHODS: Observational
study in 49 Spanish centers. Patients hospitalized because of exacerbations of
COPD (ECOPD; n224) and clinically stable patients (n153) completed the CAT
and other measures, including the Saint George’s Respiratory Disease Question-
naire (SGRQ) and the London Chest Activities of Daily Living (LCADL) instrument. In
order to replicate real-life, the CAT was self-administered (CAT-SA) or adminis-
tered by health care personnel (CAT-IA) as decided by clinicians. Multiple linear
regression analysis was used to determine whether mode of administration af-
fected scores after adjusting for differences between groups. The instrument’s
psychometric properties were compared between groups. RESULTS: Of 377 pa-
tients included, 118 (31.2%) completed the questionnaire by self-administration
and 259 (68.8%) by interview. Multiple regression analysis showed that the mode of
administration did not affect CAT scores. Psychometric properties were good
whichever mode of administration was used. Internal consistency coefficients
(Cronbach’s alpha: 0.86 for CAT-SA and 0.85 for CAT-IA) and test-retest reliability
(intraclass correlation coefficients of 0.83 for CAT-SA and CAT-IA) were high. Cor-
relations with SGRQ and LCADL were moderate to strong for both groups, though
only the CAT-IA correlated significantly with clinical measures of COPD. Similar
results were observed when testing longitudinal validity. CONCLUSIONS: The
mode of administration does not influence CAT scores and only minimally influ-
ences its psychometric properties, suggesting that data obtained using different
modes of administration can be pooled or compared. Further research is required
to determine whether sensitivity to change is affected by mode of administration.
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RELIABILITY OF A PATIENT-REPORTED ADVERSE DRUG EVENT
QUESTIONNAIRE
de Vries ST, de Zeeuw D, Haaijer-Ruskamp FM, Denig P
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OBJECTIVES: Previously, a questionnaire was developed to collect information re-
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